Por qu la OPS emiti la alerta sobre agonistas GLP-1 Segn la OPS, en los ltimos meses varios pases han reportado eventos adversos de diversa gravedad vinculados al uso de medicamentos agonistas del receptor del pptido similar al glucagn-1 (GLP-1), entre ellos semaglutida, dulaglutida, liraglutida y tirzepatida, entre otros
ASCO: Lower Incidence of Breast Cancer Seen With GLP-1 Receptor Agonist Exposure THURSDAY, June 4, 2026 -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) exposure is associated with a lower incidence of breast cancer, according to a study published online June 2 in JCO Oncology Practice to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 29 to June 2 in Chicago
Analytical and purity concerns
A significant drug main effect ( p = 0.001), as well as a trend-level drug time-point interaction effect ( p = 0.08) was also detected for GLP-1, suggesting that GLP-1 concentrations were lower under cannabis, compared to the placebo condition
Journal reference: Pearson, J
